Company News

Share this article:

IMS Health put itself up for sale, according to several reports citing people familiar with the matter. According to a Wall Street Journal report, the offers – from TPG, Silver Lake and BC Partners – are expected to give IMS stockholders a 30% premium on their shares, valuing the company at approximately $3.5 billion. Shares were up 21.6% - to $17.84 – following the WSJ report yesterday afternoon.

Bristol-Myers Squibb will cut roughly 25% of its Abilify sales force, according to a Bloomberg report. The cuts are a result of Otsuka Pharmaceuticals, a partner on the antipsychotic drug, taking over more of the marketing duties on Abilify, according to the report.  


Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.